Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P48165
UPID:
CXA8_HUMAN
Alternative names:
Connexin-50; Lens fiber protein MP70
Alternative UPACC:
P48165; A7L5M5; Q5VVN9; Q9NP25
Background:
Gap junction alpha-8 protein, also known as Connexin-50 and Lens fiber protein MP70, plays a crucial role in the structural integrity of eye lens gap junctions. These junctions are essential for cell communication, allowing small molecules and ions to diffuse between cells, thereby maintaining lens transparency and eye health.
Therapeutic significance:
The association of Gap junction alpha-8 protein with Cataract 1, multiple types, underscores its therapeutic significance. Understanding the role of Gap junction alpha-8 protein could open doors to potential therapeutic strategies for cataract, a leading cause of visual impairment and blindness.